Tositumomab and Iodine I 131 Tositumomab
This page contains brief information about tositumomab and iodine I 131 tositumomab and a collection of links to more information about the use of this drug combination, research results, and ongoing clinical trials.
Use in Cancer
As of February 2014, tositumomab and iodine I 131 tositumomab has been discontinued by the manufacturer and is no longer available.
Tositumomab and iodine I 131 tositumomab is approved to treat:
- Non-Hodgkin lymphoma (certain types). It is used in patients whose disease has not gotten better or have had a relapse after treatment with chemotherapy or rituximab. It is a type of radioimmunotherapy.
More About Tositumomab and Iodine I 131 Tositumomab
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Tositumomab and Iodine I 131 Tositumomab - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Tositumomab And Iodine I 131 Tositumomab - Check for trials from NCI's list of cancer clinical trials now accepting patients.